Sabitlenmiş Tweet
Urothelial carcinoma: 8 insights about this common bladder cancer | MD Anderson Cancer Center mdanderson.org/cancerwise/uro…
English
Omar Alhalabi, MD
2.3K posts
Omar Alhalabi, MD
@OAlhalabiMD
Genitourinary Medical Oncologist @mdandersonnews. #bladdercancer. repost≠endorsement.
Houston, TX Katılım Ocak 2017
1.4K Takip Edilen1.9K Takipçiler
Omar Alhalabi, MD retweetledi
Are #HER2-targeted #ADCs moving faster in #urothelial
cancer than our ability to define who is truly HER2-positive?
No current HER2 scoring framework was designed for urothelial tumour biology.
Now out on @NatRevUrol
@DanieleRaggi83 @Pederfizzo
doi.org/10.1038/s41585…
English
Omar Alhalabi, MD retweetledi
US nonprofit hospitals spent $7.8 billion on management consultants from 2009 to 2023, but contracts were not associated with meaningful changes in finance, operations, or quality of care. 🧵
ja.ma/4d46zfq
English
Omar Alhalabi, MD retweetledi
Bladder cancer care looks very different today than it did just a few years ago. Patients deserve to know the options.
Sat down with @DocMattCampbell to break it all down in plain language. We cover everything from the critical first steps in diagnosis to breakthrough treatments and the future of bladder preservation.
If you or a loved one is navigating a diagnosis, or you want to understand the current state of #bladdercancer care, this @CancerWise podcast is for you. 🎙️
#BladderCancerAwarenessMonth #OncSurgery @UTMDAnderson
youtu.be/lH8-Gb4acWU?si…
YouTube
English
You can see @mjmoussa_ radiating energy and enthusiasm as he discusses his research. You can feel it even without sound 🔇!
@DocMattCampbell @UroDocAsh @SurenaMatinMD @PavlosMsaouel do you agree?
GU Oncology Now@GUOncologyNow
📺 Watch @DocMattCampbell and @mjmoussa_ of @UTMDAnderson share findings from their study exploring the use of immune checkpoint inhibitors in patients with deficient mismatch repair/microsatellite instability–high #UTUC: buff.ly/YXgJYJW
English
Omar Alhalabi, MD retweetledi
Grateful to @GUOncologyNow team for highlighting our study, published in @JCOPO_ASCO!
Appreciate the mentorship of @DocMattCampbell & @OAlhalabiMD, in this work examining the meaningful benefit of single-agent ICIs in advanced UTUC with dMMR/MSI-H!
🔗: ascopubs.org/doi/10.1200/PO…
GU Oncology Now@GUOncologyNow
📺 Watch @DocMattCampbell and @mjmoussa_ of @UTMDAnderson share findings from their study exploring the use of immune checkpoint inhibitors in patients with deficient mismatch repair/microsatellite instability–high #UTUC: buff.ly/YXgJYJW
English
Omar Alhalabi, MD retweetledi
📺 Watch @DocMattCampbell and @mjmoussa_ of @UTMDAnderson share findings from their study exploring the use of immune checkpoint inhibitors in patients with deficient mismatch repair/microsatellite instability–high #UTUC: buff.ly/YXgJYJW
English
Very well deserved to our Italian friend. Congrats Manu! Hard work in science
competes with gift in baking 🧑🍳
Emanuele Crupi, MD@emanuele_crupi
Honored to receive this prestigious recognition from @ASCO & @ConquerCancerFd! Grateful to the Stadler family for their generosity. Deeply thankful to my @UTMDAnderson family & mentors, Drs. JJ Gao and Siefker-Radtke, for their unwavering support. #EndCancer #ASCO26
English
Omar Alhalabi, MD retweetledi
Registration is open for the International Urology Cancer Summit (#IUCS) 2026.
The meeting will take place in #Guildford (UK) on September 3–4, 2026, with a program focused on key advances in genitourinary oncology.
One click away
urologycancersummit.org
@gbanna74
English
Omar Alhalabi, MD retweetledi
Efficacy of Immune Checkpoint Blockade in Advanced Upper Tract Urothelial Cancer With DNA Mismatch Repair Deficiency or Microsatellite Instability.
Read the full article. bit.ly/4tTV3tW
#gucsm
English
Omar Alhalabi, MD retweetledi
@kaydaustin @ERPlimackMD @crisbergerot @NazliDizman @BradMcG04 @g_procopio_ @GGiannarini @AmandaNizamMD @DocMattCampbell @LabGenovese @salvolarosa @priyaraomd @OAlhalabiMD @perelli_luigi @rahulshethmd @ChadTangMD @TiansterZhang @QingZhangLab @BCottaMD @Daniel_J_George @IamLinghua @UroDocAsh @ChapinMD @drmehrarohit @DrDanielHeng @ED_PhD_ @DanielFrigo @rovingatuscap @katy_beckermann @shilpaonc 5/5 Bottom line: ixazomib triplet modestly boosts response but not durable control in unselected RMC. The real win is a roadmap: biomarker-guided selection&therapies targeting the stress-adaptation & stromal circuits identified here. The next generation of RMC trials starts here.
English
Omar Alhalabi, MD retweetledi
BCG shortage has forced difficult decisions in #NMIBC care. At the same time, CREST and POTOMAC reinforce a core truth: BCG immunotherapy works - very well!
The question is how to deliver it rationally, equitably, and at scale.
🧵
English
Omar Alhalabi, MD retweetledi
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
ir.revmed.com/news-releases/…
English
Omar Alhalabi, MD retweetledi
@DocMattCampbell delivering a wonderful summary of the treatment landscape post EVP at #Chriswood26
English
Omar Alhalabi, MD retweetledi
Immune Checkpoint Inhibitors in dMMR/MSI-H Advanced Upper Tract Urothelial Carcinoma - Mohammad Jad Moussa (@mjmoussa_)
@JCOPO_ASCO @DocMattCampbell @OAlhalabiMD
oncodaily.com/voices/mohamma…
#OncoDaily #Oncology #Cancer #Health #Medicine #MedX
English
@GEVaughan1 @DubauskasLim Happy bday Zita! Thank you for being a role model for our PAs @UTMDAnderson
English
Happy birthday, @DubauskasLim! The way you care for patients is truly moving, and the KCA is a better place because of you. I hope you feel all that love coming back to you today!
English
@monda_steven @mjmoussa_ @JCOPO_ASCO @DocMattCampbell @UTMDAnderson @andreevdrakhlin @AVenkatesanMD @PavlosMsaouel @BladderCancerUS @SGoswamiMDPhD @IMG_Oncologists @johnlin08 We have evaluated using IHC first and figure 1 in the paper highlights the occasional discordance with NGS and germline. However, IHC seems to be the most sensitive.
English
@mjmoussa_ @JCOPO_ASCO @DocMattCampbell @OAlhalabiMD @UTMDAnderson @andreevdrakhlin @AVenkatesanMD @PavlosMsaouel @BladderCancerUS @SGoswamiMDPhD @IMG_Oncologists @johnlin08 Super cool work. @DocMattCampbell @OAlhalabiMD how are you approaching the MMR evaluation clinically? MMR IHC first or somatic/germline panel for most UTUC (including localized)?
English
🔥👉JUST PUBLISHED in @JCOPO_ASCO – @DocMattCampbell @OAlhalabiMD @UTMDAnderson
Immune Checkpoint Inhibitors in dMMR/MSI-H Advanced Upper Tract Urothelial Carcinoma (UTUC): A Distinct Population, A Remarkable Signal
Co-led with🌟@andreevdrakhlin!
🔗shorturl.at/xPSYn 1/👇
English
Omar Alhalabi, MD retweetledi
Congratulations @mjmoussa_ @DocMattCampbell @OAlhalabiMD et al. @OncoAlert @JCOPO_ASCO @HannahRAbrams
Mohammad Jad Moussa, MD, MSc@mjmoussa_
🔥👉JUST PUBLISHED in @JCOPO_ASCO – @DocMattCampbell @OAlhalabiMD @UTMDAnderson Immune Checkpoint Inhibitors in dMMR/MSI-H Advanced Upper Tract Urothelial Carcinoma (UTUC): A Distinct Population, A Remarkable Signal Co-led with🌟@andreevdrakhlin! 🔗shorturl.at/xPSYn 1/👇
Français
Omar Alhalabi, MD retweetledi
@BladderCancerUS @Uromigos @urotoday @PGrivasMDPhD @OncoDailyIO @oncodaily @mirrorsmed @JCOPO_ASCO @GUOncologyNow @GU_Onc_PubMed @ASCOTECAG @IBCG_BladderCA 12/ I am very grateful to my mentors @UTMDAnderson for their continued support, our co-authors for their valuable contributions, our patients & patient advocates (@kaydaustin), our professional society @ASCO (& affil. @ConquerCancerFd) for championing rare GU cancer research!✌️
English
Omar Alhalabi, MD retweetledi
@BladderCancerUS @Uromigos @urotoday @PGrivasMDPhD @OncoDailyIO @oncodaily @mirrorsmed @JCOPO_ASCO @GUOncologyNow @GU_Onc_PubMed @ASCOTECAG @IBCG_BladderCA 9/ Toxicity
Grade ≥3 immune-related adverse events occurred in about one-third of patients (33%). These were manageable but clinically meaningful, reinforcing the importance of defining optimal treatment duration.
English
Omar Alhalabi, MD retweetledi
@BladderCancerUS @Uromigos @urotoday @PGrivasMDPhD @OncoDailyIO @oncodaily @mirrorsmed @JCOPO_ASCO @GUOncologyNow @GU_Onc_PubMed @ASCOTECAG @IBCG_BladderCA 8/ Some patients went on to surgical consolidation with low-stage or even pathologic complete responses. This suggests that immunotherapy may convert some cases to operability and opens the door to organ-preserving strategies!
English